Ausgabe 6/2019
Inhalt (9 Artikel)
Voriconazole: A Review of Population Pharmacokinetic Analyses
Changcheng Shi, Yubo Xiao, Yong Mao, Jing Wu, Nengming Lin
Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone
Mari Kinnunen, Panu Piirainen, Hannu Kokki, Pauliina Lammi, Merja Kokki
Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies
Neil A. Miller, Micaela B. Reddy, Aki T. Heikkinen, Viera Lukacova, Neil Parrott
A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs
Alper Daskapan, Lusiana R. Idrus, Maarten J. Postma, Bob Wilffert, Jos G. W. Kosterink, Ymkje Stienstra, Daniel J. Touw, Aase B. Andersen, Adrie Bekker, Paolo Denti, Agibothu K. Hemanth Kumar, Kidola Jeremiah, Awewura Kwara, Helen McIlleron, Graeme Meintjes, Joep J. van Oosterhout, Geetha Ramachandran, Neesha Rockwood, Robert J. Wilkinson, Tjip S. van der Werf, Jan-Willem C. Alffenaar
Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations
Pieter J. Colin, Karel Allegaert, Alison H. Thomson, Daan J. Touw, Michael Dolton, Matthijs de Hoog, Jason A. Roberts, Eyob D. Adane, Masato Yamamoto, Dolores Santos-Buelga, Ana Martín-Suarez, Nicolas Simon, Fabio S. Taccone, Yoke-Lin Lo, Emilia Barcia, Michel M. R. F. Struys, Douglas J. Eleveld
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes
Charlotte Granhall, Morten Donsmark, Thalia M. Blicher, Georg Golor, Flemming L. Søndergaard, Mette Thomsen, Tine A. Bækdal
Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery
Tomoyuki Mizuno, Katja M. Gist, Zhiqian Gao, Michael F. Wempe, Jeffrey Alten, David S. Cooper, Stuart L. Goldstein, Alexander A. Vinks
Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis
Amit Khatri, Ling Cheng, Anne Camez, Stanislav Ignatenko, Yinuo Pang, Ahmed A. Othman
Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin
Stijn W. van Beek, Rob ter Heine, Ron J. Keizer, Cecile Magis-Escurra, Rob E. Aarnoutse, Elin M. Svensson